Comparative Pharmacology
Head-to-head clinical analysis: NITROSTAT versus RECTIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROSTAT versus RECTIV.
NITROSTAT vs RECTIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is a prodrug that releases nitric oxide (NO), which activates guanylyl cyclase, increasing cGMP in vascular smooth muscle, leading to vasodilation. Preferentially dilates coronary arteries and veins, reducing preload and afterload.
RECTIV (nitroglycerin) is a nitric oxide (NO) donor that relaxes vascular smooth muscle via stimulation of intracellular cyclic guanosine monophosphate (cGMP) production, leading to vasodilation. In chronic anal fissures, it reduces internal anal sphincter pressure and improves blood flow to the anoderm.
0.3-0.6 mg sublingually or buccally every 5 minutes as needed for angina relief, up to a maximum of 3 doses in 15 minutes.
1 gram (0.5 mg nitroglycerin) applied intrarectally as an ointment 10-15 minutes before anticipated bowel movement, up to twice daily.
None Documented
None Documented
2–3 minutes for initial distribution phase; terminal elimination half-life is approximately 1–4 minutes. Rapid clearance due to extensive metabolism in the liver and other tissues (via glutathione-organic nitrate reductase).
Terminal elimination half-life is approximately 2-4 hours in healthy adults. In patients with severe hepatic impairment, half-life may be prolonged up to 8-10 hours, requiring dose adjustment.
Renal excretion of inactive metabolites accounts for approximately 60% of elimination; biliary/fecal excretion accounts for about 35%. Unchanged nitroglycerin is minimally excreted in urine (<1%).
Primarily renal; approximately 60-70% of the parent drug and metabolites excreted in urine within 24 hours. Fecal elimination accounts for ~20-30% via biliary secretion. Less than 1% unchanged drug recovered in feces.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator